GlaxoSmithKline executives jailed in China

China has fined British pharmaceuticals giant GlaxoSmithKline three billion yuan (£297 million) for paying out bribes in what is a record penalty for China, state news agency Xinhua said.

Mark Reilly, the former head of GSK in China, and other GSK executives will also be jailed for two to four years, Xinhua said.

Live updates

China fines GlaxoSmithKline £297 million for bribery

GlaxoSmithKline has been fined £297 million and its former country manager handed a suspended prison sentence in China for bribery.

GSK accepted the decision by the Changsha Intermediate People's Court in Hunan province that it had bribed doctors and hospitals to use its products, adding it has taken steps to change its working practices.

ITV News China Correspondent Lucy Watson reports from Beijing:

British GSK exec 'will not face jail time in China'

Mark Reilly, the former China head of British drugmaker GlaxoSmithKline, will be deported from China and will not face jail time in the country, Reuters has reported citing a source with direct knowledge of the matter.

"Reilly will be deported so he won't be in detention in China," said the source with knowledge of the matter who declined to be named because of the sensitivity of the case.

Advertisement

GSK 'will learn from' China bribery investigation

GlaxoSmithKline said a bribery case in China had been a "deeply disappointing matter" after a number of company executives were jailed and the firm was fined £297 million.

GSK said in a statement on their website that the activities by the firm's China unit were a "clear breach" of GSK's governance and compliance procedures.

GSK Chief Executive Officer Sir Andrew Witty said:

Reaching a conclusion in the investigation of our Chinese business is important, but this has been a deeply disappointing matter for GSK. We have and will continue to learn from this.

GSK has been in China for close to a hundred years and we remain fully committed to the country and its people. We will continue to expand access to innovative medicines and vaccines to improve their health and well-being.

We will also continue to invest directly in the country to support the government's health care reform agenda and long-term plans for economic growth.

– Sir Andrew Witty

Advertisement

Back to top